Skip to content

Turbo Cancer: Hyper-Progressive Disease in Mortality Data

Day 1 · 7:22:10 · Denis G. Rancourt, PhD · Shawn Buckley

  • 🦠 Hyper-progressive disease after immune disruption has ~300 papers since 2015; now labeled turbo cancer in COVID context.
  • 📈 U.S. 5–44 cancer deaths step up thousands; 5–24 shows ~960 excess; rare long-bone limb cancer triples after youth rollouts.
  • 🎯 Primary multi-site cancers jump (~240 ages 25–44; ~1,500 ages 75+), a lab-confirmed simultaneous multi-organ primary pattern.

Hard mortality evidence of anomalous aggressive cancers post-rollout.

← Toddler and Child Mortality Spiked at Age-Group Rollouts | GDP, Big Hospitals, and Lockdowns Drove Canadian Excess Deaths →

Transcript

Denis G. Rancourt, PhD · 7:22:10

Um, and the, the final part of the final section of Part 1 is the question of cancer mortality anomalously increasing. So the The term turbo cancer has been used earlier, and I want to show you some very definitive evidence from hard mortality data that that is indeed the case. So this is unprecedented data, and I want to first say before I show the data that the scientific phenomenon of a rapid turbo-like cancer has been well known since 2015. It is in the scientific literature. There's more than— there's approximately 300 articles about this in the scientific literature. It's termed hyper-progressive disease, and they mean cancer, HPD. And it came into being in 2015 when novel immune therapy drugs were introduced and used on people who had been subjected to particular surgeries and things things like that.

Denis G. Rancourt, PhD · 7:23:13

So as soon as they started using these novel immune therapy drugs that have just been patented and approved, they, they had this new phenomenon of very aggressive cancers spread throughout the body that could affect young people or whoever had received this therapy. So this is a well-known thing that if you mess with the immune system, you can induce rapidly progressive and very aggressive cancers.

Shawn Buckley · 7:23:40

Okay.

Denis G. Rancourt, PhD · 7:23:41

And in the COVID-19 vaccine context, it has been termed turbo cancer, but it's the same kind of phenomenon. And there is now starting to be in the scientific literature a recognition of this. This is the title of the first journal article that I could find that has the term in the title. Clinicians, of course, have been seeing this in their practices for some time and have been reporting it. And so the type of evidence I'm gonna show with regards to this cancer is temporal trends of excess cancer mortality that happen at the same time as COVID rollouts or after COVID rollouts. And so in the US, there's a lot here. Here are some of the numbers in red here. So we're looking at thousands of extra cancer deaths. And I wanna show you the statistical, the data signals that, that demonstrate illustrate this. So this is the first graph in which we're looking at the age group 5 to 44-year-olds.

Denis G. Rancourt, PhD · 7:24:42

And we see the trend there. It's, it's a bi— it's a monthly mortality. And we see the historic trend. And then you see a step up to a higher plateau. That step up to a higher plateau occurs precisely when the huge finance cuts of financial support to Americans were made. And at the same time, there was this vaccine equity surge in rollouts to the poor. Then you have, when that happens, you have this more than 4,000 excess cancer deaths, all cancer types included. If you look at the 5 to 24-year-olds in the United States, you see the characteristic bump that I've been showing you. And you can see it for males and Males, this is a definitive signal. This, this is not ambiguous. So you're looking at 960 extra cancer deaths in that age group that would not normally have occurred in the United States. And then you can look at very specific cancer types.

Denis G. Rancourt, PhD · 7:25:44

This is a very rare cancer called long bone limb cancer, and it is affecting 5 to 24-year-olds. And you, you look at the, And if you look at that huge rise, you have a tripling of the deaths from that cancer in the United States after you have rolled out the vaccines in the year and after you have rolled out to the vaccines to those ages. You have this huge rise in that very specific kind of cancer. And so that's definitely a safety signal. And then the last cancer type that I want to show you is, is a cancer type called primary multi-site cancer. So these are deaths from a very special kind of cancer. This is a cancer where you have tumors on different organs that are all primary. In other words, it's not a cancer that progressed naturally and spread where you, where you have a spread from one organ to another or to different parts of the body.

Denis G. Rancourt, PhD · 7:26:46

No, this is the spontaneous simultaneous occurrence of tumors of different primacy, of different origin on different organs. So that's a very specific diagnostic. The CDC regulates how you make that diagnostic and you have to have lab studies and so on. And there's an increase in those types of cancers that is very significant. This is the increase shown for the 25 to 44 -year-olds in the US, male and female in different colors there. And you see that large increase. So you're looking at 240 excess primary multiple site cancers in the US in the age group 25 to 44. You see the same kind of cancer shooting up a gap in the most elderly, 75-plus-year-olds. Year olds. So you see male and female, I've circled it there. You have a sudden break and you have an increase in the, in this type of cancer, which is an unusual type of cancer.

Denis G. Rancourt, PhD · 7:27:48

And you've got 1,500 excess deaths in this age group, 75 plus in the US. So there's similar signals occurring in Canada, which we're still analyzing, and I didn't want to show them yet. So I want to move on to part 2 instead.